- Home
- RARE vs IMVT Comparison
RARE vs IMVT Comparison
Compare RARE & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | IMVT |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 4.2B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | IMVT |
|---|---|---|
| Price | $36.37 | $22.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $85.20 | $27.71 |
| AVG Volume (30 Days) | 1.3M | ★ 1.3M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $630,598,000.00 | N/A |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $20.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.63 | N/A |
| 52 Week Low | $25.81 | $12.72 |
| 52 Week High | $50.00 | $29.49 |
Technical Indicators
Market Signals| Indicator | RARE | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 52.47 |
| Support Level | $33.16 | $21.93 |
| Resistance Level | $34.77 | $23.31 |
| Average True Range (ATR) | 1.52 | 0.98 |
| MACD | 0.36 | -0.29 |
| Stochastic Oscillator | 83.52 | 34.49 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.